Study of Zinc for Wilson Disease
Study of Zinc for Wilson Disease
OBJECTIVES: I. Establish the safety and efficacy of extended maintenance zinc therapy in 200
 patients with Wilson disease.

 II. Establish further the role of zinc in the prophylactic treatment of presymptomatic
 patients by increasing the current cohort from 80 to at least 100 patients.

 III. Establish further the role of zinc therapy in pregnant patients with Wilson disease.

 IV. Establish further the role of zinc therapy in children with Wilson disease.
PROTOCOL OUTLINE:

 Patients receive copper regulation therapy with zinc acetate: an existing cohort on
 maintenance therapy will be followed for long-term data collection; presymptomatic patients
 are treated prophylactically; and pregnant patients are evaluated for fetal outcome. All
 patients are evaluated for copper balance, clinical control, and toxicity.
PROTOCOL ENTRY CRITERIA: Wilson disease Presymptomatic, pregnant, and children 16 years or
 younger patients eligible Patient age: Any age, including children